$EQ
Equillium, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020039503 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.820M $2.190M $2.590M
YoY Change 28.77%
% of Gross Profit
Research & Development $3.893M $4.250M $3.759M
YoY Change -8.4% 687.04% 466.97%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $10.00K
YoY Change
% of Gross Profit
Operating Expenses $6.610M $6.439M $6.348M
YoY Change 2.66% 472.36% 512.15%
Operating Profit -$6.610M -$6.439M -$6.348M
YoY Change 2.66% 472.36% 512.15%
Interest Expense -$150.0K $380.0K $400.0K
YoY Change -139.47%
% of Operating Profit
Other Income/Expense, Net $149.0K $370.0K $398.0K
YoY Change -59.73% -157.81% -173.7%
Pretax Income -$6.460M -$6.070M -$5.950M
YoY Change 6.43%
Income Tax
% Of Pretax Income
Net Earnings -$6.461M -$6.069M -$5.950M
YoY Change 6.46% 243.85% 277.3%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$365.2K -$349.3K -$342.3K
COMMON SHARES
Basic Shares Outstanding 17.68M 17.38M 17.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.60M $56.94M $61.61M
YoY Change -25.19% 762.79%
Cash & Equivalents $24.08M $22.66M $21.39M
Short-Term Investments $18.50M $34.28M $40.21M
Other Short-Term Assets $1.600M $900.0K $1.000M
YoY Change 77.78% 800.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.20M $57.80M $62.63M
YoY Change -23.52% 762.63%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $77.00K $83.00K
YoY Change 29.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $15.00K $15.00K
YoY Change -100.0%
Total Long-Term Assets $100.0K $92.00K $98.00K
YoY Change 8.7%
TOTAL ASSETS
Total Short-Term Assets $44.20M $57.80M $62.63M
Total Long-Term Assets $100.0K $92.00K $98.00K
Total Assets $44.30M $57.89M $62.73M
YoY Change -23.47% 764.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $1.974M $1.588M
YoY Change -8.81% 558.0%
Accrued Expenses $1.600M $1.688M $1.464M
YoY Change -5.21% 181.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.400M $3.662M $3.052M
YoY Change -7.15% 306.89%
LONG-TERM LIABILITIES
Long-Term Debt $9.810M $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $100.0K $200.0K $200.0K
YoY Change -50.0% -77.78%
Total Long-Term Liabilities $9.810M $163.0K $181.0K
YoY Change 5918.4% -98.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.400M $3.662M $3.052M
Total Long-Term Liabilities $9.810M $163.0K $181.0K
Total Liabilities $13.30M $3.825M $3.233M
YoY Change 247.71% -68.9%
SHAREHOLDERS EQUITY
Retained Earnings -$27.53M -$21.46M
YoY Change
Common Stock $81.51M $80.91M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.97M $54.06M $59.49M
YoY Change
Total Liabilities & Shareholders Equity $44.30M $57.89M $62.73M
YoY Change -23.47% 764.0%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$6.461M -$6.069M -$5.950M
YoY Change 6.46% 243.85% 277.3%
Depreciation, Depletion And Amortization $10.00K $0.00 $10.00K
YoY Change
Cash From Operating Activities -$5.080M -$4.760M -$4.464M
YoY Change 6.72% 131.07% 402.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$50.00K $11.00K
YoY Change -100.0% 150.0% 120.0%
Acquisitions
YoY Change
Other Investing Activities $8.460M $6.090M -$2.640M
YoY Change 38.92%
Cash From Investing Activities $8.450M $6.040M -$2.651M
YoY Change 39.9% -30300.0% 52920.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.080M -4.760M -4.464M
Cash From Investing Activities 8.450M 6.040M -2.651M
Cash From Financing Activities 90.00K 0.000
Net Change In Cash 3.460M 1.280M -7.115M
YoY Change 170.31% -366.67% 695.86%
FREE CASH FLOW
Cash From Operating Activities -$5.080M -$4.760M -$4.464M
Capital Expenditures $0.00 -$50.00K $11.00K
Free Cash Flow -$5.080M -$4.710M -$4.475M
YoY Change 7.86% 130.88% 400.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6069000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
39000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-236000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
768000
us-gaap Net Income Loss
NetIncomeLoss
-14298000
us-gaap Net Income Loss
NetIncomeLoss
-12019000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
69000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-308000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17692731
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17376236
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17627641
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6610000
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
274000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
122000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
375000
us-gaap Investment Income Interest
InvestmentIncomeInterest
342000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
301000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
149000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
370000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6461000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-69000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-377000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
38000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
76000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6838000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6031000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14222000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
64935000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5950000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
59494000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
19000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
581000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
54063000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
252000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
787000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
453000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14062000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12787000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
83000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5463000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4778000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
6439000
us-gaap Interest Expense Debt
InterestExpenseDebt
547000
us-gaap Investment Income Interest
InvestmentIncomeInterest
773000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
82000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11937000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17376236
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24083000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22661000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7837000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
36346000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
96000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1350000
us-gaap Profit Loss
ProfitLoss
-14298000
us-gaap Profit Loss
ProfitLoss
-12019000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
15000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
11000
us-gaap Share Based Compensation
ShareBasedCompensation
2137000
us-gaap Share Based Compensation
ShareBasedCompensation
1027000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-34000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-12000
eq Non Cash Consulting Expense
NonCashConsultingExpense
81000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
130000
us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
13000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-8000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
241000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-890000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-318000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-100000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
890000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-334000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
782000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11450000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9220000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2225000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
25630000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
23700000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
29075000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21460000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3389000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
775000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
96000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
871000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-17000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10864000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5847000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13219000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28508000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Significant estimates in the Company&#8217;s condensed consolidated financial statements relate to clinical trial accruals and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2494889
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1203483
CY2020Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
18523000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
39924000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39875000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
55000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q2 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
CY2020Q2 us-gaap Interest Payable Current
InterestPayableCurrent
69000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
71000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
CY2020Q2 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2019Q2 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2019Q2 us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
0
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
0
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
994000
CY2020Q2 eq Accrued Clinical Studies
AccruedClinicalStudies
404000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
111000
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
CY2020Q2 eq Accrued Preclinical Research
AccruedPreclinicalResearch
48000
CY2019Q4 eq Accrued Preclinical Research
AccruedPreclinicalResearch
15000
CY2019Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2019Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
300000
CY2020Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Two
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearTwo
1667000
CY2020Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Three
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearThree
3333000
CY2020Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Four
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearFour
3333000
CY2020Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Five
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearFive
2117000
CY2020Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFee
10450000
CY2020Q2 eq Unaccreted Liability For Final Payment Fee
UnaccretedLiabilityForFinalPaymentFee
345000
CY2020Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
295000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
9810000
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9810000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1475093
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2020Q2 eq Number Of Non Management Directors
NumberOfNonManagementDirectors
2
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1350000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
581000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2137000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1027000
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4224363
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3218710

Files In Submission

Name View Source Status
0001564590-20-039503-index-headers.html Edgar Link pending
0001564590-20-039503-index.html Edgar Link pending
0001564590-20-039503.txt Edgar Link pending
0001564590-20-039503-xbrl.zip Edgar Link pending
eq-10q_20200630.htm Edgar Link pending
eq-20200630.xml Edgar Link completed
eq-20200630.xsd Edgar Link pending
eq-20200630_cal.xml Edgar Link unprocessable
eq-20200630_def.xml Edgar Link unprocessable
eq-20200630_lab.xml Edgar Link unprocessable
eq-20200630_pre.xml Edgar Link unprocessable
eq-ex101_26.htm Edgar Link pending
eq-ex311_6.htm Edgar Link pending
eq-ex312_7.htm Edgar Link pending
eq-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending